PI3K inhibitors, such as copanlisib and idelalisib [16], have shown promising therapeutic efficacy and have been clinically approved for use in several tumor types such as lymphoma and breast cancer [18, 19], and also demonstrated certain clinical activity in BCa therapy. This evidence concerns the gene PIK3CA and breast carcinoma.